Peripheral blood mononuclear cells (PBMCs) are among the most widely used primary human cells in biomedical research. Their accessibility, diversity of immune cell subsets, and clinical relevance make them a powerful tool for both disease modeling and biomarker discovery. By leveraging PBMC in biomarker discovery and disease modeling, researchers can simulate immune system activity, uncover disease pathways, and accelerate the development of diagnostics and therapeutics.
Why PBMCs Are Valuable for Disease Modeling
Applications in Understanding Disease
PBMCs contain a heterogeneous mix of immune cells—primarily T cells, B cells, natural killer (NK) cells, and monocytes—that play essential roles in orchestrating immune responses. This diversity allows researchers to:
-
Recreate disease-relevant immune environments in vitro, without the need for invasive tissue biopsies.
-
Study cellular interactions that drive autoimmune disease, infection, cancer progression, or transplant rejection.
-
Test novel therapies ex vivo, such as checkpoint inhibitors, CAR-T approaches, or small molecules, in a patient-relevant system.
For example, PBMCs isolated from donors with autoimmune diseases (such as lupus or rheumatoid arthritis) can replicate inflammatory pathways, helping scientists better understand immune dysregulation. Similarly, PBMCs from oncology patients provide insight into immune exhaustion and tumor–immune dynamics.
PBMCs as a Source for Discovery
PBMC in Biomarker Discovery
The role of PBMCs extends beyond modeling—these cells are a rich source of molecular and cellular biomarkers. PBMCs can be profiled to:
-
Identify gene expression signatures that predict disease onset, progression, or therapeutic response.
-
Discover novel surface markers on immune cells that distinguish diseased states from healthy controls.
-
Evaluate cytokine and chemokine production, revealing immune activity patterns that correlate with clinical outcomes.
-
Develop companion diagnostics by linking PBMC-derived biomarkers to treatment responses in clinical trials.
With the growth of single-cell sequencing and multiomics technologies, PBMCs are increasingly used to generate high-resolution immune maps—allowing researchers to uncover subtle yet clinically meaningful biomarkers.
Applications Across Therapeutic Areas
-
Autoimmune Disease: PBMCs reveal mechanisms of chronic inflammation and help identify predictive biomarkers for flares in lupus, multiple sclerosis, and Sjögren’s syndrome.
-
Oncology: PBMCs serve as a minimally invasive window into tumor–immune interactions, aiding immunotherapy development.
-
Infectious Disease: PBMC responses to viral or bacterial antigens guide vaccine design and help uncover correlates of protection.
-
Translational Medicine: Matched PBMCs with serum, plasma, or tissue provide a holistic view of systemic immune activity.
Looking Ahead: PBMCs as a Bridge from Bench to Bedside
As precision medicine advances, PBMCs will continue to serve as a bridge between basic immunology and clinical application. Their versatility allows researchers to not only model disease processes but also discover and validate biomarkers that move quickly into diagnostics and therapeutic monitoring.
By integrating PBMC in biomarker discovery with other biospecimens—such as serum, plasma, and tissue—researchers can develop a more complete picture of disease biology, paving the way for breakthroughs in early detection and targeted treatment.
At Sanguine, we provide high-quality PBMCs from both healthy and disease-state donors, processed under IRB-approved protocols with extensive De-identified Donor Data. Whether you’re focused on disease modeling, biomarker discovery, or translational studies, our samples are designed to help accelerate your research.
Curious about other immune cells?
We also offer healthy and disease-state leukopaks, CD3+ T cells, CD19+ B cells, and CD56+ NK cells.
Further Reading on PBMC in Biomarker Discovery and Disease Modeling
Additional Reading on PBMCs from Sanguine:
PBMC Applications in Current Medical Research Trends
Example Publications using PBMC in Biomarker Discovery and Disease Modeling:
ZBTB2 represses HIV-1 transcription and is regulated by HIV-1 Vpr and cellular DNA damage responses